How to optimize HCV therapy in genotype 1 patients: predictors of response
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
How to optimize HCV therapy in genotype 1 patients: predictors of response
Authors
Keywords
-
Journal
LIVER INTERNATIONAL
Volume 33, Issue -, Pages 23-29
Publisher
Wiley
Online
2013-01-03
DOI
10.1111/liv.12053
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir
- (2012) Fred Poordad et al. GASTROENTEROLOGY
- Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naïve patients infected with HCV genotype 1
- (2012) Lawrence Serfaty et al. GUT
- New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
- (2012) Christoph Welsch et al. GUT
- Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
- (2012) Calogero Cammà et al. HEPATOLOGY
- Informed deferral: A moral requirement for entry into the hepatitis C virus treatment warehouse
- (2012) Andrew Aronsohn et al. HEPATOLOGY
- Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin
- (2012) Ira M. Jacobson et al. HEPATOLOGY
- Genomics and HCV infection: Progression of fibrosis and treatment response
- (2012) Emilie Estrabaud et al. JOURNAL OF HEPATOLOGY
- Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response
- (2011) Andrew J. Muir et al. HEPATOLOGY
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
- (2011) Marc G. Ghany et al. HEPATOLOGY
- Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment
- (2011) Patrick R. Harrington et al. HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
- (2011) JOURNAL OF HEPATOLOGY
- Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow
- (2011) Tarik Asselah et al. LIVER INTERNATIONAL
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
- (2011) Kenneth E. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
- (2010) Alexander J. Thompson et al. GASTROENTEROLOGY
- Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C
- (2010) Patrick Marcellin et al. GASTROENTEROLOGY
- Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
- (2010) Paul Y Kwo et al. LANCET
- Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis
- (2009) Christophe Moreno et al. JOURNAL OF HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation